

Omicron BA.4/BA.5 escape neutralizing immunity elicit

Nature Communications

13,

DOI: [10.1038/s41467-022-32396-9](https://doi.org/10.1038/s41467-022-32396-9)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. <i>Science Immunology</i> , 2022, 7, .	5.6	144
4	Emergence of novel omicron hybrid variants: BA(x), XE, XD, XF more than just alphabets. <i>International Journal of Surgery</i> , 2022, 104, 106727.	1.1	15
5	Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1116-1117.	4.6	49
6	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. <i>Cell</i> , 2022, 185, 2422-2433.e13.	13.5	532
7	Molecular dynamics studies reveal structural and functional features of the SARS-CoV-2 spike protein. <i>BioEssays</i> , 2022, 44, .	1.2	9
8	Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. <i>Reviews in Medical Virology</i> , 2022, 32, .	3.9	276
9	Sublineages of the SARS-CoV-2 Omicron variants: Characteristics and prevention. <i>MedComm</i> , 2022, 3, .	3.1	15
10	A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. <i>Journal of Virology</i> , 2022, 96, .	1.5	14
12	Genomic Surveillance of SARS-CoV-2 in the Southern Province of Zambia: Detection and Characterization of Alpha, Beta, Delta, and Omicron Variants of Concern. <i>Viruses</i> , 2022, 14, 1865.	1.5	1
13	Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron Variant. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	24
14	Moving targets: COVID-19 vaccine efficacy against Omicron subvariants. <i>Molecular Therapy</i> , 2022, 30, 2644-2645.	3.7	6
15	Strain wars 5: Gibbs energies of binding of BA.1 through BA.4 variants of SARS-CoV-2. <i>Microbial Risk Analysis</i> , 2022, 22, 100231.	1.3	11
16	Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations. <i>Communications Biology</i> , 2022, 5, .	2.0	9
18	Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection. <i>Journal of Clinical Virology</i> , 2022, 156, 105273.	1.6	19
19	Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 29, 100586.	1.3	6
20	Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe. <i>Journal of Infectious Diseases</i> , 2022, 226, 1396-1400.	1.9	7
21	Covid-19 Vaccines "Immunity, Variants, Boosters. <i>New England Journal of Medicine</i> , 2022, 387, 1011-1020.	13.9	266
24	Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection. <i>Cell Reports Medicine</i> , 2022, 3, 100764.	3.3	16

#	ARTICLE	IF	CITATIONS
25	Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
26	Are Nutraceuticals Effective in COVID-19 and Post-COVID Prevention and Treatment?. <i>Foods</i> , 2022, 11, 2884.	1.9	16
27	Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 45-55.	4.6	55
28	Immune Evasion of SARS-CoV-2 Omicron Subvariants. <i>Vaccines</i> , 2022, 10, 1545.	2.1	19
29	Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. <i>Cell</i> , 2022, 185, 3992-4007.e16.	13.5	167
31	The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies. <i>Drug Resistance Updates</i> , 2022, 65, 100882.	6.5	31
32	First Detection of the SARS-CoV-2 Omicron BA.5/22B in Monaco. <i>Microorganisms</i> , 2022, 10, 1952.	1.6	2
33	How will previous infection or current vaccination strategies protect us from future SARS-CoV-2 variant infections?. , 2022, 1, .		0
34	Genomic Transcriptome Benefits and Potential Harms of COVID-19 Vaccines Indicated from Optimized Genomic Biomarkers. <i>Vaccines</i> , 2022, 10, 1774.	2.1	3
35	Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
37	Tracing the international arrivals of SARS-CoV-2 Omicron variants after Aotearoa New Zealand reopened its border. <i>Nature Communications</i> , 2022, 13, .	5.8	12
40	A Pathway Model to Understand the Evolution of Spike Protein Binding to ACE2 in SARS-CoV-2 Variants. <i>Biomolecules</i> , 2022, 12, 1607.	1.8	1
41	Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6. <i>New England Journal of Medicine</i> , 2022, 387, 1904-1906.	13.9	43
42	Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. <i>Cell Host and Microbe</i> , 2022, 30, 1540-1555.e15.	5.1	96
43	A multinational Delphi consensus to end the COVID-19 public health threat. <i>Nature</i> , 2022, 611, 332-345.	13.7	103
46	First Imported Case of SARS-CoV-2 Omicron Subvariant BA.4 in Guangdong Province, China, May 4, 2022. <i>China CDC Weekly</i> , 2022, 4, 902-903.	1.0	4
47	Ad26.COVS priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. <i>IScience</i> , 2023, 26, 105753.	1.9	4
48	Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa. <i>International Journal of Infectious Diseases</i> , 2023, 127, 63-68.	1.5	32

#	ARTICLE	IF	CITATIONS
49	Protection against SARS-CoV-2 BA.4 and BA.5 subvariants via vaccination and natural infection: A modeling study. <i>Mathematical Biosciences and Engineering</i> , 2022, 20, 2530-2543.	1.0	1
50	The Omicron-transformer: Rise of the subvariants in the age of vaccines. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 712-729.	0.2	9
51	Advancing disease genomics beyond COVID-19 and reducing health disparities: what does the future hold for Africa?. <i>Briefings in Functional Genomics</i> , 0, , .	1.3	1
52	Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. <i>Cell Host and Microbe</i> , 2023, 31, 9-17.e3.	5.1	163
53	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
54	Emergence of BA.4/BA.5 Omicron Sub-lineages and Increased SARS-CoV-2 Incidence in Senegal. <i>Coronaviruses</i> , 2022, 04, .	0.2	1
55	Inferring selection effects in SARS-CoV-2 with Bayesian Viral Allele Selection. <i>PLoS Genetics</i> , 2022, 18, e1010540.	1.5	8
56	Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa. <i>Clinical Infectious Diseases</i> , 2023, 76, 1468-1475.	2.9	15
57	Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo. <i>Science Advances</i> , 2022, 8, .	4.7	9
58	Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. <i>Nature</i> , 0, , .	13.7	187
59	Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant. <i>Cell Reports Medicine</i> , 2023, 4, 100910.	3.3	5
60	Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada. <i>Cmaj</i> , 2022, 194, E1599-E1609.	0.9	25
61	Omicron variants of SARS-CoV-2 and long COVID. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
62	Modelling the dynamics of infection, waning of immunity and re-infection with the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand. <i>Epidemics</i> , 2022, 41, 100657.	1.5	10
63	The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. <i>Virologica Sinica</i> , 2022, 37, 786-795.	1.2	12
64	Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy. <i>Aids</i> , 2023, 37, 709-721.	1.0	9
65	Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals. <i>Vaccines</i> , 2022, 10, 2132.	2.1	6
66	Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. <i>Nature Communications</i> , 2023, 14, .	5.8	54

#	ARTICLE	IF	CITATIONS
68	SARS-CoV-2 Omicron BA.5 Infections in Vaccinated Persons, Rural Uganda. <i>Emerging Infectious Diseases</i> , 2023, 29, 224-226.	2.0	3
69	Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	0
70	SARS-CoV-2 variant biology: immune escape, transmission and fitness. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	160
72	Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients. <i>American Journal of Transplantation</i> , 2023, 23, 423-428.	2.6	8
73	SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals. <i>Viruses</i> , 2023, 15, 101.	1.5	5
74	Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. <i>Genome Medicine</i> , 2022, 14, .	3.6	12
75	Transmission cluster characteristics of global, regional, and lineage-specific SARS-CoV-2 phylogenies. , 2022, , .		1
76	A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants. <i>Science China Life Sciences</i> , 2023, 66, 1818-1830.	2.3	11
77	Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5. <i>Viruses</i> , 2023, 15, 312.	1.5	9
78	Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination—Evidence Synthesis and Implications for New COVID-19 Vaccines. <i>Biomedicines</i> , 2023, 11, 370.	1.4	15
79	Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants. <i>International Journal of Infectious Diseases</i> , 2023, 129, 19-31.	1.5	6
81	Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	4
82	Novel pro-and eukaryotic expression plasmid expressing omicron antigens delivered via <i>Salmonella</i> elicited MHC class I and II based protective immunity. <i>Journal of Controlled Release</i> , 2023, 357, 404-416.	4.8	3
83	Perioperative fatal thrombotic complication after elective meningioma resection in asymptomatic SARS-CoV-2 BA.5.2 (Omicron variant) infection. , 2023, 6, 100131.		0
84	The Spread of SARS-CoV-2 Omicron Variant in CALABRIA: A Spatio-Temporal Report of Viral Genome Evolution. <i>Viruses</i> , 2023, 15, 408.	1.5	6
85	Modelling the impact of the Omicron BA.5 subvariant in New Zealand. <i>Journal of the Royal Society Interface</i> , 2023, 20, .	1.5	9
87	Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	0
88	Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron. <i>Viruses</i> , 2023, 15, 530.	1.5	1

#	ARTICLE	IF	CITATIONS
89	When to update COVID-19 vaccine composition. <i>Nature Medicine</i> , 2023, 29, 776-780.	15.2	9
90	Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone. <i>Current Issues in Molecular Biology</i> , 2023, 45, 1741-1761.	1.0	2
91	Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. <i>Nature Methods</i> , 2023, 20, 512-522.	9.0	111
92	A DNA Vaccine Encoding the Full-Length Spike Protein of Beta Variant (B.1.351) Elicited Broader Cross-Reactive Immune Responses against Other SARS-CoV-2 Variants. <i>Vaccines</i> , 2023, 11, 513.	2.1	5
93	Perceptions into causes and consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. <i>Rheumatology & Autoimmunity</i> , 2023, 3, 1-8.	0.3	0
95	Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron. <i>Cytokine and Growth Factor Reviews</i> , 2023, 70, 13-25.	3.2	17
96	Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COVS.S-primed individuals: Comparison by breakthrough infection. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
97	A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. <i>Immunotherapy Advances</i> , 2023, 3, .	1.2	2
99	Hybrid immunity provides protective advantage over vaccination or prior remote COVID-19 alone. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	2
100	Protection from Omicron Infection in Residents of Nursing and Retirement Homes in Ontario, Canada. <i>Journal of the American Medical Directors Association</i> , 2023, 24, 753-758.	1.2	6
101	Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	4
102	An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies. <i>AIMS Microbiology</i> , 2023, 9, 375-401.	1.0	4
103	Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses. <i>PLoS Pathogens</i> , 2023, 19, e1010870.	2.1	11
104	Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 1875-1885.	1.4	3